Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, has had its clinical trial application for the domestically produced injectable GenSci136 accepted by the National Medical Products Administration [1] Group 1: Product Development - Injectable GenSci136 is a Class 1 therapeutic biological product independently developed by Jinsai Pharmaceutical, intended for the treatment of Immunoglobulin A Nephropathy (IgAN) [1] - The drug functions as a B-cell maturation antigen (BCMA) trimeric fusion protein, capable of binding to B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL) [1] - GenSci136 has the potential to block the interaction between BlyS, APRIL, and B cell membrane receptors, which may help in treating various autoimmune diseases characterized by fluid immune disorders and tissue damage caused by pathogenic antibodies [1]

Core Viewpoint - AstraZeneca has submitted an application for the approval of gefurulimab in China, targeting generalized myasthenia gravis (gMG) as its indication, based on clinical trial progress [1] Group 1: Product Information - Gefurulimab is a mini bispecific antibody (25kD) that includes a variable region of the antibody heavy chain targeting C5 and an antibody fragment that specifically binds to albumin [1] - The smaller molecular weight of gefurulimab allows for better permeability, and its binding to albumin extends its half-life [1] Group 2: Disease Context - Generalized myasthenia gravis (gMG) is a rare, debilitating, chronic autoimmune neuromuscular disease that leads to muscle function loss and severe weakness [2] - Initial symptoms of gMG may include slurred speech, diplopia, ptosis, and weakness, with progression leading to more severe symptoms such as extreme fatigue, difficulty swallowing, choking, and respiratory failure [2]

Core Viewpoint - The announcement from Valiant Biopharma-B (09887) highlights the successful administration of the first subject in the Phase I clinical trial of LBL-047, focusing on its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy [1] Group 1: Clinical Trial Details - The Phase I study is a randomized, double-blind, placebo-controlled, single ascending dose trial conducted in healthy adults and patients with systemic lupus erythematosus (SLE) [1] - The healthy volunteer segment is led by Professor Meng Xianmin from Shanghai Public Health Clinical Center, while the SLE segment is overseen by Professors Ye Shuang and Chen Sheng from Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine [1] Group 2: Drug Mechanism and Potential - LBL-047 is a bispecific fusion protein composed of a humanized anti-BDCA2 antibody and a modified transmembrane activator and calcium-modulating cyclophilin ligand (TACI) extracellular domain [1] - The drug selectively eliminates plasmacytoid dendritic cells (pDC) to reduce type I interferon production and inhibits the B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) signaling pathways, thereby blocking B-cell activation, differentiation, and antibody production [1] - This differentiated approach targets two major driving factors of autoimmune disease pathogenesis, indicating potential for treating various autoimmune indications [1] - LBL-047 has also been optimized to extend its half-life through Fc region modification [1]

Core Viewpoint - The announcement from Valiant Biopharma-B (09887) highlights the successful administration of the first subject in the Phase I clinical trial of LBL-047, focusing on its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy [1] Group 1: Clinical Trial Details - The Phase I study is a randomized, double-blind, placebo-controlled, single ascending dose trial conducted in healthy adults and patients with systemic lupus erythematosus (SLE) [1] - The trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy of LBL-047 [1] - The healthy volunteer segment is led by Professor Meng Xianmin from Shanghai Public Health Clinical Center, while the SLE segment is led by Professors Ye Shuang and Chen Sheng from Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine [1] Group 2: Drug Mechanism and Potential - LBL-047 is a bispecific fusion protein composed of a humanized anti-BDCA2 antibody and a modified transmembrane activator and calcium-modulating cyclophilin ligand (TACI) extracellular domain [1] - The drug selectively eliminates plasmacytoid dendritic cells (pDCs) to reduce type I interferon production and inhibits the B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) signaling pathways, thereby blocking B-cell activation, differentiation, and antibody production [1] - This differentiated approach targets two major driving factors of autoimmune disease pathogenesis, indicating potential for treating various autoimmune indications [1] - LBL-047 has also been optimized to extend its half-life through Fc region modification [1]

Group 1 - The core point of the news is that Innovent Biologics has received approval from the National Medical Products Administration (NMPA) to conduct Phase II clinical trials for its novel TYK2 inhibitor ICP-488, aimed at treating Cutaneous Lupus Erythematosus (CLE) [1] - ICP-488 is an oral, highly selective TYK2 allosteric inhibitor that blocks the signaling of inflammatory cytokines such as IL-23, IL-12, and type I interferons, thereby inhibiting the pathological processes of autoimmune and inflammatory diseases [1] - CLE is a common type of lupus characterized by diverse skin lesions, with some patients potentially progressing to systemic lupus erythematosus affecting internal organs [1] Group 2 - Innovent Biologics is a commercial-stage biopharmaceutical high-tech company focused on the development of novel drugs for malignant tumors and autoimmune diseases [2] - The company has multiple new drug products at various stages of commercialization, clinical trials, and preclinical development [2] - Innovent Biologics has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [2]

Core Viewpoint - Nocera Biopharma's new TYK2 inhibitor soficitinib has received approval for II/III clinical trials for treating chronic spontaneous urticaria (CSU), which is expected to enhance the company's market position in the dermatology sector [1][2] Company Summary - Nocera Biopharma's stock rose over 4%, currently trading at 13.69 HKD with a transaction volume of 37.91 million HKD [1] - Soficitinib is a highly selective oral TYK2 inhibitor developed for various T-cell related autoimmune diseases, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, nodular prurigo, and urticaria [1] - The approval from the National Medical Products Administration (NMPA) marks a significant milestone for the company in advancing its clinical pipeline [1] Industry Summary - There are approximately 50 million patients suffering from chronic spontaneous urticaria globally, with the CSU market projected to reach 3 billion USD by 2029 [2]

Group 1 - The core point of the article is that Nocera Biopharma (09969) has seen its stock price increase by over 4% following the announcement of the approval for its new TYK2 inhibitor, soficitinib, to conduct Phase II/III clinical trials for chronic spontaneous urticaria (CSU) [1] - Soficitinib is a highly selective oral TYK2 inhibitor developed by the company, aimed at treating various T-cell related autoimmune diseases, with a focus on dermatological conditions such as atopic dermatitis, vitiligo, nodular prurigo, and urticaria [1] - TYK2 is a key kinase in the JAK-STAT signaling pathway, playing an important role in the inflammatory disease mechanism, and soficitinib works by blocking cytokine signaling pathways that drive mast cell activation and inflammation, thereby alleviating symptoms of CSU [1] Group 2 - There are approximately 50 million patients suffering from chronic spontaneous urticaria globally, and the CSU market is projected to reach $3 billion by 2029 [2]

Company Overview - Hemay Pharmaceutical Co., Ltd. (referred to as "Hemay") submitted its second prospectus to the Hong Kong Stock Exchange on December 1, 2025, aiming for a main board listing, with Guotai Junan Securities as the sole sponsor [1] - Established in 2002, Hemay focuses on the discovery and development of proprietary small molecule drugs for autoimmune diseases and tumors, maintaining a leading position in the development of treatments for psoriasis, Behçet's disease, and inflammatory bowel disease [1] Financial Performance - For the fiscal year ending December 31, 2024, Hemay reported other income of approximately RMB 0.05 billion and a net loss of RMB 1.23 billion, with a 20% year-on-year increase in net loss for the first half of 2025 [1][6] - In the first half of 2025, other income was RMB 0.04 billion, with a net loss of RMB 0.73 billion, reflecting a 26.93% year-on-year increase in net loss [7] - The company’s cash flow from operating activities was -RMB 0.52 billion as of June 30, 2025, with cash reserves of approximately RMB 0.73 billion at year-end [7] Product Pipeline - Hemay has developed seven small molecule drug candidates, including its core product Mufemilast, which has received NDA approval in China for the treatment of moderate to severe plaque psoriasis [2] - Hemay022, another candidate, is undergoing a Phase III clinical trial for advanced ER+/HER2+ breast cancer [3] - Mufemilast is also being evaluated for Behçet's disease in a pivotal Phase III trial and has received orphan drug designation from the FDA [2] Market Potential - The psoriasis drug market in China is projected to reach RMB 18.2 billion by 2024, with a compound annual growth rate (CAGR) of 30.5% from 2019 to 2024, and is expected to grow to RMB 48.3 billion by 2028 [8] - The market for Behçet's disease drugs in China is anticipated to grow from RMB 490 million in 2019 to RMB 666.6 million by 2024, with a CAGR of 6.4% [12] Competitive Landscape - As of the latest data, there are 17 approved targeted therapies for psoriasis in China, including five small molecule drugs and twelve biologics, with some showing superior efficacy in head-to-head clinical trials [11] - Hemay's Mufemilast is positioned against established treatments like Apremilast, which has been recommended in clinical guidelines for Behçet's disease [15] Comparable Companies - Hemay's peer in the industry, Qianxin Biopharmaceutical-B (2509.HK), had an IPO on March 20, 2024, with a market capitalization of approximately HKD 4.397 billion [16]

Company Overview - Hangzhou Gaoguang Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with CICC and CMB International as joint sponsors [1] - The company focuses on developing safe and effective therapies for patients with autoimmune and inflammatory diseases, particularly in the challenging field of neuroinflammation, with a unique advantage in world-class candidates for treating Alzheimer's and Parkinson's diseases [1] Product Pipeline - The core products TLL-018, TLL-041, and TLL-009 are the only highly selective TYK2/JAK1 inhibitors globally [4] - TLL-018 is expected to be a first-in-class and best-in-class therapy for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA), with two Phase III trials currently underway in China [4] - TLL-041 is the first and only brain-penetrant selective TYK2/JAK1 inhibitor, targeting neurodegenerative diseases, and the collaboration with Biohaven is the largest publicly disclosed transaction in China's neurodegenerative disease sector [4] Financial Performance - The company's revenue decreased from approximately RMB 225.6 million in 2023 to RMB 0 in 2024, primarily due to upfront payments received from licensing agreements [6] - The company recorded a profit of RMB 73.79 million in 2023 but is projected to incur losses of approximately RMB 226.37 million in 2024 and RMB 190.35 million in 2025 [7] Industry Overview - The global pharmaceutical market is expected to grow from USD 1.32 trillion in 2019 to USD 1.54 trillion in 2024, with a CAGR of 3.1%, and further expand to USD 2.41 trillion by 2033 [8] - The Chinese pharmaceutical market is projected to grow at a CAGR of 3.5%, reaching RMB 1.87 trillion by 2028 and RMB 2.68 trillion by 2033 [8] - The global autoimmune disease drug market is expected to grow from USD 116.9 billion in 2019 to USD 143.1 billion in 2024, with a CAGR of 5.8% from 2024 to 2028 [10]

Company Overview - Hangzhou Gaoguang Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with CICC and China Merchants International as joint sponsors [1] - The company focuses on developing safe and effective therapies for patients with autoimmune and inflammatory diseases, particularly in the challenging field of neuroinflammation, with a unique advantage in world-class candidate drugs for Alzheimer's and Parkinson's diseases [1] Product Pipeline - The core products TLL-018, TLL-041, and TLL-009 are the only highly selective TYK2/JAK1 inhibitors globally, with TLL-018 expected to be a first-in-class and best-in-class therapy for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA) [4] - The company is conducting two Phase III registration trials for CSU and RA in China and plans to submit a New Drug Application (NDA) to the National Medical Products Administration by the end of 2026 [4] - TLL-041 is the first and only brain-penetrant selective TYK2/JAK1 inhibitor for neurodegenerative disease treatment, with a significant collaboration with Biohaven, marking the largest publicly disclosed transaction in China's neurodegenerative disease sector [4] Financial Performance - The company's revenue is projected to decrease from approximately RMB 225.6 million in 2023 to zero in 2024, primarily due to upfront payments received from licensing agreements with Biohaven and Jianyi Tengchuan [6] - The company recorded a profit of RMB 73.79 million in 2023 but is expected to incur losses of approximately RMB 226.37 million in 2024 and RMB 190.35 million in 2025, driven by operational expenses and changes in the fair value of financial instruments [7] Industry Overview - The global pharmaceutical market is expected to grow from USD 1.32 trillion in 2019 to USD 1.54 trillion in 2024, with a compound annual growth rate (CAGR) of 3.1%, and further expand to USD 2.41 trillion by 2033, with a CAGR of 5.3% from 2028 to 2033 [8] - The Chinese pharmaceutical market is projected to grow at a CAGR of 3.5%, reaching RMB 1.87 trillion by 2028 and RMB 2.68 trillion by 2033, driven by demographic changes and healthcare reforms [8] - The global autoimmune disease drug market is expected to grow from USD 116.9 billion in 2019 to USD 143.1 billion in 2024, with further growth anticipated to USD 217 billion by 2033 [9]